Perth nano-biotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has contracted North Carolina-based R&D organisation Cirrus Pharmaceuticals to develop a number of specific drug candidates formulated in Psivida's modified silicon product BioSilicon. [ + ]

WA agriculture minister Kim Chance has claimed that concerns over a canola crop which may have contained some genetically modified material have supported the state's moratorium on GM crops. [ + ]

Solbec Pharmaceuticals' (ASX:SBP) devil's apple-derived drug Coramsine (SBP002) has met the primary endpoint of safety and tolerability for the two-hour infusion cohort of its single agent phase I clinical trial for advanced solid tumours. [ + ]

The second patient to receive Sunshine Heart's (ASX:SHC) C-Pulse device has had the device removed one month after it was implanted, after he developed a related infection. [ + ]

Sydney drug re-engineering company Eiffel Technologies (ASX:EIF) has released its results for the 2004-05 financial year, showing losses of AUD$3.5 million -- down 8.3 per cent from the previous year -- but less than $630,000 cash in the bank. [ + ]

Perth-based Bone Medical (ASX:BNE) has signed a share purchase agreement with UK R&D company Proxima Concepts to acquire 100 per cent control of British biopharma firm Bone -- the company that holds the licenses to Bone Medical's platform technologies. [ + ]

Melbourne-based Genetic Technologies (ASX:GTG) has listed its Level II American Depositary Receipts (ADRs) on the US Nasdaq national market. [ + ]

Dr Richard Opara, a substantial shareholder in biotech companies Polartechnics (ASX:PLT) and Avantogen (ASX:ACU), is trying to raise money for a new start-up capital biotech fund, but is finding the going tough in Australia and may have to go overseas to find the cash. [ + ]

The fastest and cheapest way yet of identifying and tracking the bugs that cause major human infections is being trialled at Queensland University of Technology (QUT).

South Australian genomics company Bionomics (ASX:BNO) has received a notice of allowance for a US patent, forming part of the company's patent portfolio covering a diagnostic test for severe forms of childhood epilepsy. [ + ]

Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure. [ + ]

Tissue-engineering biomedical company Clinical Cell Culture (ASX:CCE, C3) has posted record revenues of AUD$1.4 million, up 51 per cent in the 18 month period from January 1, 2004 to June 30, 2005 (2003: $0.95 million). [ + ]

The Bio21 Molecular Medicine Informatics Model (Bio21:MMIM) is one of nine projects to share $19.4 million in recent funding from the Australian government under the Systemic Infrastructure Initiative (SII). [ + ]

Researchers at Melbourne's Peter MacCallum Cancer Centre have begun testing a high-precision, antibody-mediated system to deliver short-range radionuclides to cancerous cells. [ + ]

Cancer therapy developer Meditech (ASX:MTR) has received an AusIndustry Commercial Ready Grant worth $2.988 million over the next three years towards the development and commercialisation of HyCAMP, its lead anti-cancer product which is in phase II clinical testing. Meditech has also reported a half year loss of $1.68 million and a cash balance of $3.4 million. [ + ]